BioSpace News Archive

According to Research Study, global glycomics market size is expected to reach around USD 3.5 billion by 2030 and is anticipated to grow at a CAGR of 14.10% during forecast period 2022 to 2030.

According to Report Study, the Plasma Protein Therapeutics Market size was accounted at US$ 24.38 billion in 2021 and is expected to reach US$ 52.15 billion by 2030 with a CAGR of 7.6% from 2022 to 2030.

The global Network Point-of-Care Glucose Testing market size is expected to be surpass around US$ 5.6 billion by 2030 from valued at US$ 3.3 billion in 2020 and is anticipated to grow at a CAGR of 5.10% from 2021 to 2030.

According to Vision Research Reports, the global recombinant plasma protein therapeutics market size is expected to reach US$ 21.7 bn by 2030 and anticipated expand at a CAGR of 9.2% from 2022 to 2030.

University of South Florida’s (USF) Morsani College of Medicine, in collaboration with Tampa General Hospital (TGH), is pleased to have contributed to the PREVENT-19 trial sponsored by Novavax and the COVID-19 Vaccine Prevention Network, which resulted in the fourth COVID-19 vaccine in the U.S.

BIOTRONIK, Inc. announced today that it has entered into a civil settlement with the U.S. Department of Justice, the U.S. Attorney’s Office for the Central District of California, and the U.S. Department of Health and Human Services, Office of Inspector General, to resolve historical claims of alleged overuse of paid consultants to train field personnel and limited instances of excessive customer meals and travel.

Biogénesis Bagó announced its consortium with the South Korean company FVC for the construction of a world class site that will produce up to 100 million doses of FMD vaccine per year.

Veltex Corporation (OTCQB:VLXC) (“Veltex”), a Health and Wellness Acquisition Firm, is pleased to announce its successful uplisting from the OTC Pink Market to the OTCQB® Venture Market (the “OTCQB”) effective for trading July 25, 2022 at the open.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.